Literature DB >> 8284597

Respiratory complications in Brazilian patients infected with human immunodeficiency virus.

A Weinberg1, M I Duarte.   

Abstract

PURPOSE: To determine how often and by what means an indentifiable pulmonary pathogen can be recognized in human immunodeficiency virus (HIV) infected patients with respiratory disorders in Brazil, which are the most frequently observed microorganisms and what impact specific therapy has on these agents. PATIENTS AND METHODS: Thirty-five HIV seropositive subjects with respiratory complaints were studied. All patients had a complete history, physical examination and blood counts. The pulmonary assessment included chest radiograms; sputum examination for bacterial and fungal pathogens; bronchoscopy with bronchoalveolar lavage and transbronchial biopsy. Patients with treatable complications received standard antimicrobial therapy.
RESULTS: One or more microorganisms were found in 24 subjects and another 3 individuals showed nonspecific interstitial pneumonitis. The sputum examination identified the pulmonary pathogens in 7 cases. The bronchoalveolar lavage and the histopathologic examination were diagnostic in 14% and 83%, respectively, of the 28 individuals that were submitted to bronchoscopy. The most frequently identified microorganism was P. carinii (55%), followed by M. tuberculosis (41%) and cytomegalovirus (8%). The clinical, laboratory and radiographic findings failed to distinguish the specific pulmonary pathogens. Twenty-three individuals with P. carinii pneumonitis and/or tuberculosis received specific therapy; among the evaluable patients the therapeutic response rates were 79% for PCP and 100% for TB.
CONCLUSIONS: We have determined that tuberculosis, P. carinii and cytomegalovirus pneumonitis are the most common respiratory opportunistic diseases in Brazilian patients infected with HIV. The histologic evaluation was crucial in order to identify the pulmonary pathogens. Tuberculosis in AIDS individuals displayed clinical and radiographic findings atypical for reactivation disease. However, most of the features observed in HIV infected patients had been previously described in infection of the normal host. Furthermore, the AIDS subjects showed a good therapeutic response to anti-tuberculous drugs.

Entities:  

Keywords:  Acquired Immunodeficiency Syndrome; Americas; Brazil; Developing Countries; Diseases; Examinations And Diagnoses; Hiv Infections; Infections; Laboratory Examinations And Diagnoses; Latin America; Physical Examinations And Diagnoses; Research Report; Respiratory Infections; South America; Tuberculosis; Viral Diseases

Mesh:

Year:  1993        PMID: 8284597     DOI: 10.1590/s0036-46651993000200004

Source DB:  PubMed          Journal:  Rev Inst Med Trop Sao Paulo        ISSN: 0036-4665            Impact factor:   1.846


  4 in total

Review 1.  Pneumocystis jirovecii pneumonia in developing countries.

Authors:  Y de Armas Rodríguez; G Wissmann; A L Müller; M A Pederiva; M C Brum; R L Brackmann; V Capó de Paz; E J Calderón
Journal:  Parasite       Date:  2011-08       Impact factor: 3.000

Review 2.  Current epidemiology of Pneumocystis pneumonia.

Authors:  Alison Morris; Jens D Lundgren; Henry Masur; Peter D Walzer; Debra L Hanson; Toni Frederick; Laurence Huang; Charles B Beard; Jonathan E Kaplan
Journal:  Emerg Infect Dis       Date:  2004-10       Impact factor: 6.883

Review 3.  Pneumocystis jirovecii pneumonia in tropical and low and middle income countries: a systematic review and meta-regression.

Authors:  David M Lowe; Molebogeng X Rangaka; Fabiana Gordon; Chris D James; Robert F Miller
Journal:  PLoS One       Date:  2013-08-02       Impact factor: 3.240

4.  Respiratory Complications in Iranian Hospitalized Patients with HIV/AIDS.

Authors:  Seyed Ahmad Seyed Alinaghi; Bahram Vaghari; Maryam Roham; Banafsheh Moradmand Badie; Sara Jam; Maryam Foroughi; Gholamreza Esmaeeli Djavid; Mahboubeh Hajiabdolbaghi; Mostafa Hosseini; Minoo Mohraz; Willi McFarland
Journal:  Tanaffos       Date:  2011
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.